Sun Pharma Share Price: Sun Pharmaceutical Industries Ltd., one of India’s largest pharmaceutical companies, reported a robust 28% increase in net profit for the second quarter of FY2025, far surpassing market estimates. The company’s consolidated net profit for Q2 stood at ₹3,040 crore, significantly up from ₹2,375 crore in the same period last year, driven by strong growth in both domestic and international markets.
Financial Highlights: Revenue, EBITDA, and Growth in Key Markets
Sun Pharma’s revenue from operations rose by 9% year-on-year, reaching ₹13,291 crore in Q2, supported by steady growth across its core markets. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) surged 24% to ₹3,939 crore, with an EBITDA margin of 29.6%, underscoring Sun Pharma’s operational strength and efficiency. This impressive margin outpaced analysts’ estimates, which had predicted a more conservative profit increase.
Growth in Domestic and US Markets Bolsters Overall Performance
Sun Pharma’s domestic formulation sales grew by 11% YoY, contributing ₹4,265 crore in Q2 and accounting for approximately 32% of total consolidated sales. The domestic growth was driven by seasonal demand and increased volumes in key therapeutic areas, solidifying Sun Pharma’s leadership in India. In the US, formulation sales surged 20% YoY to $517 million, making up 33% of total sales, as Sun Pharma continued to expand its presence in this lucrative market.
Additionally, sales in emerging markets reached $293 million, marking a 3% YoY increase. However, formulation sales in the Rest of the World (ROW) markets dipped slightly by 3% YoY to $199 million, reflecting a dynamic but challenging landscape.
API Business and R&D Investments: Strengthening Future Prospects
Sun Pharma’s Active Pharmaceutical Ingredient (API) external sales rose by 7% YoY to ₹534 crore. This vertical integration through its API segment enhances Sun Pharma’s supply chain for formulations, positioning it well to meet growing demand. The company also reaffirmed its commitment to innovation with consolidated R&D investments amounting to ₹793 crore during the quarter. This includes a new partnership with Philogen to commercialize Fibromun, a promising late-stage candidate in the dermatology pipeline.
Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, highlighted the importance of these investments, stating, “Our API business imparts benefits of vertical integration and continuity of supply chain for our formulations business. We continue to focus on increasing API supply for captive consumption for key products.”
Outlook and Market Reaction: Positive Momentum for Sun Pharma Shares
Sun Pharma’s strong Q2 performance has positioned the company well in both domestic and international markets, with analysts remaining optimistic about sustained revenue growth. Ahead of the Q2 results, Sun Pharma shares were already under focus, and with this robust financial report, they are expected to attract further interest from investors.
With shares now in demand, Sun Pharma is also looking to maintain its growth trajectory through targeted expansions in its specialty product portfolio. As global markets evolve, the company’s focus on cash flow management and pipeline development strengthens its position in the global pharmaceutical landscape.
Disclaimer: This article is for informational purposes only and should not be considered financial or investment advice. Readers are encouraged to conduct their own research or consult a financial advisor before making any investment decisions.
